Wolfgang Gunther - West Chester PA Kenneth Kellar - Wayne PA Dennis Kiyoshi Fujii - Downingtown PA Vinay Desai - Wayne PA Christopher Black - Wayne PA Marshall Beeber - Royersford PA Jennifer Wellons - Wayne PA Anne Kjersti Fahlvik - Oslo, NO Jasbir Singh - Gilbertsville PA Edward Richard Bacon - Wayne PA Gregory Lynn McIntire - Wayne PA Robert Alan Snow - Wayne PA Brian Weekley - Wayne PA Torgrim Engell - Oslo, NO Michel Gacek - Hovik, NO David Lee Ladd - Wayne PA Anne Naevestad - Oslo, NO George Na - Wayne PA Barbara Yuan - Wayne PA Jack Stevens - Wayne PA
Assignee:
Amersham Health AS - Oslo
International Classification:
A61B 5055
US Classification:
424 9322, 424 93, 424 932, 424 91
Abstract:
The invention relates to MR contrast media containing composite nanoparticles, preferably comprising a superparamagnetic iron oxide core provided with a coating comprising an oxidatively cleaved starch coating optionally together with a functionalized polyalkyleneoxide which serves to prolong blood residence.
Jo Klaveness - Nycoveien, NO Bjorn Fuglass - Nycoveien, NO PÃ¥l Rongved - Nycoveien, NO Edvin Johannesen - Nycoveien, NO Paul Mark Hendrichs - Wayne PA Wolfgang Hans Heinrich Gunther - Wayne PA Edward Richard Bacon - Wayne PA John Luke Toner - Wayne PA Gregory Lynn McIntire - Wayne PA Vinay C. Desai - Phoenixville PA
Assignee:
Amersham Health AS - Oslo
International Classification:
A61K 4900
US Classification:
424 96, 424 91
Abstract:
The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.
Method Of Coating A Metal Substrate With A Radioactive Layer
Robert Snow - West Chester PA Gregory McIntire - West Chester PA Edward Bacon - Audubon PA Evan Gustow - Villanova PA
Assignee:
Amersham, PLC - Little Chalfont
International Classification:
C23C 1816
US Classification:
148283, 148253, 148243, 148264
Abstract:
A method for the immobilization of a radioactive anion on the surface of a metal substrate, said method comprising treating the substrate with an oxidizing agent in the presence of a solution of a radioactive anion which forms an insoluble salt with ions of said metal. Preferably, a binding agent will also be present. Preferably, the metal is silver, the radioactive anion is I and the binding agent comprises bromide ions.
Gregory McIntire - West Chester PA Robert Snow - West Chester PA Edward Bacon - Audubon PA Morten Eriksen - Oslo, NO Auden Tornes - Oslo, NO Geraldine Cooney - Gilbertsville PA Virginia Ann Gates - Collegeville PA Joel Cornacoff - Audubon PA Christopher Black - Norristown PA
Assignee:
Amersham PLC - Buckinghamshire
International Classification:
A61B 800
US Classification:
600439, 600 3, 600 8
Abstract:
Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of a surface of the container is roughened, shaped or otherwise treated so that it is no longer smooth. The surface treatment may enhance the ultrasound visibility of the source and/or reduce the tendency of the source to migrate once implanted in a patients body. Preferred radioisotopes are palladium-103 and iodine-125.
Gregory McIntire - West Chester PA Robert Snow - West Chester PA Edward Bacon - Audubon PA Morten Eriksen - Oslo, NO Auden Tornes - Oslo, NO Geraldine Cooney - Gilbertsville PA Christopher Black - Norristown PA Joel Cornacoff - Audubon PA Virginia Ann Gates - Collegeville PA
Assignee:
Amersham PLC - Little Chalfont
International Classification:
A61N 500
US Classification:
600 1, 424 129
Abstract:
Radioactive sources, preferably radioactive seeds, for use in brachytherapy comprising a radioisotope within a sealed biocompatible container, wherein at least one part of a surface of the container is roughened, shaped or otherwise treated so that it is no longer smooth. The surface treatment may enhance the ultrasound visibility of the source and/or reduce the tendency of the source to migrate once implanted in a patients body. Preferred radioisotopes are palladium-103 and iodine-125.
Dewi M. Lewis - Prestwood, GB Lucinda A. Dollimore - Gerrards Cross, GB Nigel Powell - Reading, GB Gregory L. McIntire - West Chester PA, US Evan Gustow - Villanova PA, US Robert A. Snow - West Chester PA, US
Assignee:
GE Healthcare Limited - Buckinghamshire
International Classification:
A61N 5/00
US Classification:
600 3, 600 1, 600 7, 600 8
Abstract:
The invention provides the use of a radiation source which is a low energy X-ray emitter, e. g. with an energy of emission of the principal photon in the range of 20 to 100 keV, preferably 20 to 40 keV and with a half life of 10 to 100 days, preferably 15 to 70 days, for the treatment of restenosis. Suitable radioisotopes include palladium-103, dysprosium-159, samarium-145, cadmium-109, ytterbium-169 and preferably iodine-125. High activity radioactive bodies and sources comprising such radioisotopes, and methods for the manufacture of such sources, are also disclosed.
Jo Klaveness - Olso, NO Bjorn Fuglaas - Olso, NO Pål Rongved - Oslo, NO Edvin Johannesen - Oslo, NO Paul Mark Henrichs - Wayne PA, US Wolfgang Hans Heinrich Gunther - Wayne PA, US Edward Richard Bacon - Wayne PA, US John Luke Toner - Wayne PA, US Gregory Lynn McIntire - Wayne PA, US Vinay C. Desai - Pheonixville PA, US
Assignee:
Amersham Health AS - Oslo
International Classification:
A61K 49/00
US Classification:
424 96, 424 961, 424 91
Abstract:
The present invention relates to the use of particulate materials as contrast agents in in vivo light imaging.
Dewi Lewis - Prestwood, GB Lucinda Dollimore - Gerrards Cross, GB Nigel Powell - Reading, GB Gregory McIntire - West Chester PA, US Evan Gustow - Villanoa PA, US Robert Snow - West Chester PA, US
International Classification:
A61N 5/00
US Classification:
600003000
Abstract:
The invention provides the use of a radiation source which is a low energy X-ray emitter, e.g. with an energy of emission of the principal photon in the range of 20 to 100 keV, preferably 20 to 40 keV and with a half life of 10 to 100 days, preferably 15 to 70 days, for the treatment of restenosis. Suitable radioisotopes include palladium-103, dysprosium-159, samarium-145, cadmium-109, ytterbium-169 and preferably iodine-125. High activity radioactive bodies and sources comprising such radioisotopes, and methods for the manufacture of such sources, are also disclosed.